SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen
Aselage, chief executive officer, will present at the Jefferies 2018 London Healthcare Conference in London, UK on Wednesday,
November 14, 2018 at 4:40 p.m. GMT (11:40 a.m. ET).
A live webcast of the presentation will be available at ir.retrophin.com/events and an archived replay will be accessible for up to 30 days.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing
therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring late-stage assets targeting
rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated
neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for
focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney
often leading to end-stage renal disease. Research in additional rare diseases is also underway, including a joint development
arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to
neurological and behavioral impairment. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial
products Chenodal®, Cholbam® and Thiola®.
Retrophin.com
Contact:
Chris Cline, CFA
Vice President, Investor Relations & Corporate Communications
760-260-8600
IR@retrophin.com
